Accord’s 12-Year-Old Prograf Generic Has US Equivalence Rating Pulled
FDA Funded Studies Reveal Increased Risk Of Toxicity For Accord’s Transplant Drug
Executive Summary
Accord Healthcare has been told by the FDA that its generic version of Astellas Pharma’s Prograf capsules will no longer be automatically substituted for the brand following a series of post-approval studies dating back more than a decade.
You may also be interested in...
New US FDA-funded study aims to alleviate generic Prograf-switching concerns
The US FDA is to fund a new study at the University of Cincinnati (UC) aimed at ending questions over generic versus brand, and generic versus generic, for tacrolimus – an immunosuppressive drug for transplant patients.
Astellas drops US FDA lawsuit over generic tacrolimus
Astellas has dropped a legal action against the US FDA, which it brought in August following an agency decision not to grant the company's citizen petition on the use of oral immunosuppressants in organ transplant patients.
Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’
Following the formation of their partnership nearly five years ago, Alvotech and Fuji have together welcomed approval in Japan for Alvotech’s biosimilar to Stelara (ustekinumab).